香港批准 HUTCMED 的 ELUNATE®（呋喹替尼）治疗成人转移性结直肠癌，这是十年来首个口服靶向治疗药物，也是新“1+1”下的首个口服靶向治疗药物 Hong Kong approves HUTCHMED's ELUNATE® (fruquintinib) for metastatic colorectal cancer in adults, first oral targeted therapy in a decade and first under new "1+1"

HUTCMED 的 ELUNATE®（呋喹替尼）疗法已在香港获得上市许可，用于治疗既往接受过治疗的转移性结直肠癌成年患者。 HUTCHMED has received marketing approval for its ELUNATE® (fruquintinib) treatment in Hong Kong for adult patients with previously treated metastatic colorectal cancer. 这是香港近十年来首个针对该适应症获批的口服靶向治疗药物，也是首个在新药注册“1+1”机制下获批的药物。 This is the first oral targeted therapy approved in Hong Kong for this indication in nearly a decade and is the first medicine to be approved under the new "1+1" mechanism for registering new drugs. ELUNATE®现已在中国大陆、澳门特别行政区和美国获得批准。 ELUNATE® is now approved in mainland China, Macau SAR, and the United States.